Clinical Trial Update: Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and tolerability of BL-1020 in hospitalized patients with schizophrenia or schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Bl-1020

Snippet

Sponsor: BioLineRx, Ltd. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED